Stanford Medicine researchers demonstrate new way to temporarily heighten hypnotizablity

Ab­b­Vie has tout­ed Skyrizi as a key pil­lar of its fu­ture be­yond Hu­mi­ra, and on Thurs­day, the com­pa­ny read out re­sults sug­gest­ing the IL-23 in­hibitor

Note that some links may require registration or subscription. Though case counts on the whole remain low, the CDC is reporting an uptick in COVID